Association of platelet response to cilostazol with clinical outcome and CYP genotype in patients with cerebral infarction

摘要

Introduction: Cilostazol, an anti-platelet drug that inhibits phosphodiesterase 3, is beneficial for patients with atherothrombosis. In contrast to other anti-platelet drugs such as aspirin and thienopyridines, little information is available on the relationship between platelet responses to cilostazol and clinical outcomes.